吉非替尼与多西他赛治疗晚期非小细胞肺癌的临床效果比较

目的 对比分析吉非替尼与多西他赛治疗晚期非小细胞肺癌的临床效果.方法 选择晚期非小细胞肺癌患者96例,随机分为吉非替尼组与多西他赛组,每组48例.吉非替尼组口服吉非替尼治疗,每次250 mg,每天1次;多西他赛组静脉滴注多西他赛75 mg/m2治疗,静脉滴注1 h,每个月静脉滴注1次.比较2组的近期疗效,生活质量情况,中位生存期和1年生存率;观察2组骨髓抑制、恶心呕吐、腹泻、皮疹以及心血管反应等不良反应发生率.结果 吉非替尼组的疾病控制率以及总有效率均明显高于多西他赛组(P<0.05);吉非替尼组的躯体功能、情绪功能、角色功能和社会功能评分均明显高于多西他赛组(P<0.05);吉非替尼组的中位生存期和1年生存率均明显优于多西他赛组(P<0.05);吉非替尼组的不良反应发生率为12.50%(6/48),明显低于多西他赛组的33.33%(16/48)(P<0.05).结论吉非替尼治疗晚期非小细胞肺癌的临床效果明显优于多西他赛,且不良反应少,安全性高,具有较高的临床应用价值.

Comparison of Clinical Efficacy of Gefitinib and Docetaxel in the Treatment of Advanced Non-small Cell Lung Cancer

Objective To compare and analyze the clinical efficacy of gefitinib and docetaxel in the treatment of ad-vanced non-small cell lung cancer. Methods 96 patients with advanced non-small cell lung cancer were randomly divided into gefitinib group and docetaxel group,with 48 cases in each group. Gefitinib group was treated with gefitinib for 250 mg once daily;Docetaxel group was treated with docetaxel for intravenous infusion of 75 mg/m2 ,Intravenous infusion of 1 h,intravenous infusion once a month. The short-term efficacy, quality of life, median survival and 1-year survival rates were compared between the 2 groups. The incidence of adverse reactions such as myelosuppression,nausea and vomiting,diarrhea,rash and cardiovascular re-sponse were observed. Results The control rate and total effective rate of gefitinib group were significantly higher than that of do-cetaxel group (P<0. 05);The body function,emotional function,role function and social function score of gefitinib group were significantly higher than that of docetaxel group (P<0. 05);The median survival and 1-year survival rates of gefitinib group were significantly better than those of docetaxel group (P<0. 05). The incidence of adverse events in gefitinib group was 12. 50% (6/48),which was significantly lower than that of docetaxel group (33. 33%,16/48) (P<0. 05). Conclusion Clinical effect of gefitinib in the treatment of advanced non-small cell lung cancer is superior to docetaxel,with less adverse reactions and higher safety,and it has high clinical value.